Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration

Open Forum Infect Dis. 2022 Mar 22;9(5):ofac157. doi: 10.1093/ofid/ofac157. eCollection 2022 May.


Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.

Keywords: direct-acting antivirals; hepatitis C virus; mathematical modeling; response-guided therapy; time to cure.